These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 38841827)

  • 1. Pancreatic and cardiometabolic complications of severe hypertriglyceridaemia.
    Bashir B; Ferdousi M; Durrington P; Soran H
    Curr Opin Lipidol; 2024 Aug; 35(4):208-218. PubMed ID: 38841827
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Updates in Drug Treatment of Severe Hypertriglyceridemia.
    Gouni-Berthold I; Schwarz J; Berthold HK
    Curr Atheroscler Rep; 2023 Oct; 25(10):701-709. PubMed ID: 37642858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Severe Hypertriglyceridaemia and Chylomicronaemia Syndrome-Causes, Clinical Presentation, and Therapeutic Options.
    Bashir B; Ho JH; Downie P; Hamilton P; Ferns G; Datta D; Cegla J; Wierzbicki AS; Dawson C; Jenkinson F; Delaney H; Mansfield M; Teoh Y; Miedzybrodzka Z; Haso H; Durrington PN; Soran H
    Metabolites; 2023 Apr; 13(5):. PubMed ID: 37233662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Severe hypertriglyceridemia: Existing and emerging therapies.
    Malick WA; Do R; Rosenson RS
    Pharmacol Ther; 2023 Nov; 251():108544. PubMed ID: 37848164
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of efficacy and safety of antisense inhibition of apolipoprotein C-III with volanesorsen in patients with severe hypertriglyceridemia.
    D'Erasmo L; Gallo A; Di Costanzo A; Bruckert E; Arca M
    Expert Opin Pharmacother; 2020 Oct; 21(14):1675-1684. PubMed ID: 32646313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel therapeutics in hypertriglyceridaemia and chylomicronaemia.
    García Díaz JD
    Med Clin (Barc); 2020 Apr; 154(8):308-314. PubMed ID: 31932043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Volanesorsen in the Treatment of Familial Chylomicronemia Syndrome or Hypertriglyceridaemia: Design, Development and Place in Therapy.
    Esan O; Wierzbicki AS
    Drug Des Devel Ther; 2020; 14():2623-2636. PubMed ID: 32753844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in Dyslipidaemia Treatments: Focusing on ApoC3 and ANGPTL3 Inhibitors.
    Tomlinson B; Wu QY; Zhong YM; Li YH
    J Lipid Atheroscler; 2024 Jan; 13(1):2-20. PubMed ID: 38299167
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification and diagnosis of patients with familial chylomicronaemia syndrome (FCS): Expert panel recommendations and proposal of an "FCS score".
    Moulin P; Dufour R; Averna M; Arca M; Cefalù AB; Noto D; D'Erasmo L; Di Costanzo A; Marçais C; Alvarez-Sala Walther LA; Banach M; Borén J; Cramb R; Gouni-Berthold I; Hughes E; Johnson C; Pintó X; Reiner Ž; van Lennep JR; Soran H; Stefanutti C; Stroes E; Bruckert E
    Atherosclerosis; 2018 Aug; 275():265-272. PubMed ID: 29980054
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment options for severe hypertriglyceridemia (SHTG): the role of apheresis.
    Ewald N; Kloer HU
    Clin Res Cardiol Suppl; 2012 Jun; 7(Suppl 1):31-5. PubMed ID: 22528130
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Familial chylomicronemia syndrome: an under-recognized cause of severe hypertriglyceridaemia.
    Baass A; Paquette M; Bernard S; Hegele RA
    J Intern Med; 2020 Apr; 287(4):340-348. PubMed ID: 31840878
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Management of Hypertriglyceridemia in the Prevention of Cardiovascular Disease and Pancreatitis.
    Hernandez P; Passi N; Modarressi T; Kulkarni V; Soni M; Burke F; Bajaj A; Soffer D
    Curr Atheroscler Rep; 2021 Sep; 23(11):72. PubMed ID: 34515873
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rare Variants in Triglycerides-Related Genes Increase Pancreatitis Risk in Multifactorial Chylomicronemia Syndrome.
    Paquette M; Amyot J; Fantino M; Baass A; Bernard S
    J Clin Endocrinol Metab; 2021 Aug; 106(9):e3473-e3482. PubMed ID: 34019660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of therapies for chylomicronemia.
    Shamsudeen I; Hegele RA
    Expert Rev Clin Pharmacol; 2022 Apr; 15(4):395-405. PubMed ID: 35762447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical heterogeneity in monogenic chylomicronaemia.
    Heidemann BE; Bemelmans RHH; Marais AD; Visseren FLJ; Koopal C
    BMJ Case Rep; 2022 Nov; 15(11):. PubMed ID: 36423940
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of chylomicronemia.
    Navarro Hermoso A; Valdivielso P
    Clin Investig Arterioscler; 2021 May; 33 Suppl 2():75-79. PubMed ID: 34006359
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological treatment options for severe hypertriglyceridemia and familial chylomicronemia syndrome.
    Chaudhry R; Viljoen A; Wierzbicki AS
    Expert Rev Clin Pharmacol; 2018 Jun; 11(6):589-598. PubMed ID: 29842811
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Familial Chylomicronemia Syndrome (FCS): Recent Data on Diagnosis and Treatment.
    Gallo A; Béliard S; D'Erasmo L; Bruckert E
    Curr Atheroscler Rep; 2020 Aug; 22(11):63. PubMed ID: 32852651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intensive genetic analysis for Chinese patients with very high triglyceride levels: Relations of mutations to triglyceride levels and acute pancreatitis.
    Jin JL; Sun D; Cao YX; Zhang HW; Guo YL; Wu NQ; Zhu CG; Gao Y; Dong QT; Liu G; Dong Q; Li JJ
    EBioMedicine; 2018 Dec; 38():171-177. PubMed ID: 30420299
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypertriglyceridaemia in adolescents may have serious complications.
    Korf M; Zöllner EW; Solomon GEA; Zemlin AE; Marais AD
    S Afr Med J; 2022 Apr; 112(5):307-312. PubMed ID: 35587241
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.